Medisyn Technologies develops pre-qualified proprietary drug compounds. Our platform, Forward Engineering™, is focused on predicting the behavior of molecules from their topology (structural characteristics). We can analyze and optimize currently existing drugs or develop new drug candidates for our partners and ourselves.
Our breakthrough in silico (computer) technology helps our clients design new or improved drug candidates faster and more effectively than they can themselves. We also provide testing and analysis services to predict safety (the ADME/Toxicity properties) and efficacy of compounds. Our predictive accuracy is greater than 85% for bioactive compound identification - a truly phenomenal accomplishment.
Pharmaceutical companies spend $50 Billion annually in research and development of new drugs. On average, these companies are screening 400,000 compound candidates just to get to a single commercially viable drug. The average cost of the current process is over $800 million per drug.
By utilizing Medisyn's Forward Engineering™ technology, pharmaceutical companies can save up to 9 years and $300 Million in traditional research and development costs per drug developed. Over the past year alone, Medisyn's platform has produced patent-pending compounds for disease treatments or health promotion in multiple therapeutic areas.
Chief Executive Officer
David is a senior executive with diverse experience in general management, sales, marketing, customer care, IT and operations. He has an extensive international background working with Fortune 50 and start-up companies alike. Before Medisyn, David was Vice President with Jostens, an $800 million achievement recognition and celebration events company. David held executive roles with Lenox, Inc. in operations, IT and sales after beginning his career in a variety of systems engineering positions. He earned a diploma (equivalent to bachelor's degree) from Seminaire Adventiste du Saleve in France following studies in mathematics at Loma Linda University, California and studies in mathematics, physics and chemistry at Bournemouth Junior College in England.
Kevin Lynch - Chairman
CEO, Volerro Corporation
Henry A. Cousineau III - Director
President, Entropy Solutions, Inc.
Mark Kroll, Ph.D. - Director
former Senior Vice President and Chief Technology Officer, St. Jude Medical, Inc.
David Land - Director
CEO, Medisyn Technologies
Jack Meyer - Director
former CEO of Urologix, Fiberoptic Sensor Technology, Carelink
Steven Pederson - Director
Partner, Sherpa Partners LLC
Ian Troup - Director
former COO, Upsher-Smith
James E. Brewer
Arkadiusz Dudek, M.D., Ph.D.
Medical Director of Clinical Trials for the University of Illinois Cancer Center
Dr. Jorge Gálvez
Senior Professor of Pharmacy, University of Valencia
Molecular Topology & Physical Chemistry
Dr. Kim Janda
Professor, Department of Chemistry
The Scripps Research Institute
Dr. Christopher A. Lipinski
Senior Research Fellow, Pfizer Global R&D (retired)
Thomas R. Parr, Jr., Ph.D.
Chief Scientific Officer, Spero Therapeutics
Dr. George Wilcox
Professor of Pharmacology, University of Minnesota Medical School
Pharmacology & Pain, Bioengineering
Medisyn Technologies is a valued research partner committed to providing biotech partners and research collaborators with scientific support in bioactive compound and extract development projects in the areas of pharmaceutical, nutraceutical, animal health, and agrichemical via development agreements, strategic alliances and long-term partnerships.
Medisyn is able to assist companies of all sizes with their needs - from novel drug and bioactive ingredient screening to lead optimization to de novo design.
A few of our valued customers:
Research and licensing collaboration with Kraft Foods Global Inc. to discover effective bioactive ingredients suitable for food use.
Small Business Innovation Research (SBIR) Phase I grant from the Department of Defense (DoD) to discover and develop new non-steroidal anti-inflammatory drugs (NSAIDs) with reduced gastrointestinal toxicity.
Collaboration for the development of novel β-amyloid (Aβ) lowering drugs as a treatment in Alzheimer’s disease. In vitro evidence substantiates that Medisyn's technology was successful in building a predictive model for Aβ-lowering activity. Validated and characterized lead compounds will be out-licensed to pharmaceutical companies for further clinical development. Commercialization rights will be shared between MSSM and Medisyn Technologies.
Discovery collaboration for the development of small molecules targeting inflammatory and neurological diseases. The collaboration is based on the discovery technology platforms available at each company and will serve to develop pre-clinically validated lead compounds within joint and airway inflammations as well as Multiple Sclerosis, pain relief and Parkinson’s Disease.
Multi-year strategic alliance to accelerate the discovery and development of natural, non-prescription compounds focused on disease prevention.
Collaborative research agreement Invitrogen’s Drug Discovery Solutions group extends an earlier working relationship between the two companies. This collaboration builds upon a previously successful evaluation with Invitrogen’s GibcoTM subsidiary in which Medisyn’s predictive technology was applied to the areas of cell culture media improvement. The results discovered in the GibcoTM project were nonobvious and indicated that Medisyn’s technology could be practically applied to specialty media development. This latest research agreement called for the use of Medisyn’s molecular topology-based Fast Forward EngineeringTM platform to optimize chemical modulators of kinase function.
Medisyn has created intellectual property for clients in a number of therapeutic areas. In addition, Medisyn has an IP portfolio of its own oncology candidates that are available for out-license.
|Description||Country of Issue||Date||Serial Number||Therapeutic Category|
|Therapeutic agents and corresponding treatments (MT103 + 6 analogs)||US||July 19, 2005||US 6,919,376||NSCLC/PKC Inhibition|
|Therapeutic agents and corresponding treatments (MT103 + 6 analogs)||Canada||April 19, 2011||CA 2,499,523||NSCLC/PKC Inhibition|
|Therapeutic agents and corresponding treatments (MT103 + 6 analogs)||Japan||March 5, 2010||JP No. 4469720||NSCLC/PKC Inhibition|
|Therapeutic agents and corresponding treatments (MT103 + 6 analogs)||France||March 12, 2008||EU Patent 02792178.2||NSCLC/PKC Inhibition|
|Therapeutic agents and corresponding treatments (MT103 + 6 analogs)||Germany||March 12, 2008||EU Patent 02792178.2||NSCLC/PKC Inhibition|
|Therapeutic agents and corresponding treatments (MT103 + 6 analogs)||Switzerland||March 12, 2008||EU Patent 02792178.2||NSCLC/PKC Inhibition|
|Therapeutic agents and corresponding treatments (MT103 + 6 analogs)||UK||March 12, 2008||EU Patent 02792178.2||NSCLC/PKC Inhibition|
|Therapeutic agents and corresponding treatments (MT477 + analogs)||US||January 26, 2010||US 7,652,029l||Pancreatic/Ras Pathway|
|Therapeutic agents and corresponding treatments (additional analogs of MT477)||US Continuation||January 3, 2012||US 8,088,785||Pancreatic/Ras Pathway|
|Therapeutic agents and corresponding treatments (MT477 + analogs)||Canada||Pending||2573190||Pancreatic/Ras Pathway|
|Therapeutic agents and corresponding treatments (MT477 + analogs)||Japan||July 27, 2012||JP No. 5049124||Pancreatic/Ras Pathway|
|Therapeutic agents and corresponding treatments (MT477 + analogs)||Europe||Pending||5765609.2||Pancreatic/Ras Pathway|
|Therapeutic agents and corresponding treatments (MT477)||China||November 23, 2011||CN No. 867517||Pancreatic/Ras Pathway|
Medisyn Technologies, Inc. an emerging stage biotechnology company focused on discovering new treatments for cancer, infectious diseases and Alzheimer's disease.
Key investors include:
Atlas Capital Partners
AC Partners portfolio is focused on early stage and emerging growth companies that are in various areas of innovation. They do not specialize in a single market vertical, but instead look for entrepreneurs with a proven product that is post-revenue, on the verge of rapid growth, and possesses a defensible competitive advantage. They specifically seek opportunities where human capital can add significant value. Their portfolio reflects a personal mission to leave the world in a better place than it was found. acpartners.us
Sherpa Partners, LLC
Sherpa Partners, LLC is a Minneapolis-based venture capital firm focused on early-stage companies in the Upper Midwest. We have decades of personal experience in the high-altitude, rarified air of new enterprises. As experienced operational managers, we are investing time, energy and money to help Midwest-based emerging technology companies create the strategies, systems, infrastructure and management teams to become leaders in their markets. www.sherpapartners.com
Portage Capital, run by Brad Lehrman and Beatrice Rothweiler, is a business and venture capital consulting firm specializing in emerging growth companies at critical stages of development. www.portagecapital.com
StarTec Investments, LLC
StarTec Investments, LLC. is a private venture capital firm founded in 1998 by Joy J. Lindsay and Thomas J. McLeod, Sr. The primary investment focus of StarTec is early-stage technology companies located in Minnesota. www.startecinv.com
Proceeds from future financing will be used to increase the discovery and testing of promising lead drug candidates. Medisyn already has multiple patent-pending therapeutic compounds in its portfolio for license to pharmaceutical partners.
If you are interested in funding opportunities and learning more about Medisyn's technology, please contact us.